P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS

• Jan Bewersdorf,
• Helen Ajufo,
• Claire Harrison,
• Francesca Palandri,
• John Mascarenhas,
• Jeanne Palmer,
• Aaron T. Gerds,
• Jean-Jacques Kiladjian,
• Andrii Derkach,
• Karisse Roman-Torres,
• Sarah Buckley,
• Raajit K Rampal

Affiliations

Jan Bewersdorf

1 Memorial Sloan Kettering Cancer Center, New York, United States

Helen Ajufo

1 Memorial Sloan Kettering Cancer Center, New York, United States

Claire Harrison

2 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Francesca Palandri

3 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy

John Mascarenhas

4 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai,, New York, United States

Jeanne Palmer

5 Mayo Clinic, Scottsdale, United States

Aaron T. Gerds

6 Cleveland Clinic Taussig Cancer Institute, Cleveland, United States

Jean-Jacques Kiladjian

7 Hôpital Saint-Louis, Université de Paris, Paris, France

Andrii Derkach

1 Memorial Sloan Kettering Cancer Center, New York, United States

Karisse Roman-Torres

8 CTI BioPharma Corp., Seattle, United States

Sarah Buckley

8 CTI BioPharma Corp., Seattle, United States

Raajit K Rampal

1 Memorial Sloan Kettering Cancer Center, New York, United States